Updates

[vc_row][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_column_text]

Updates

  • Monday, January 8, 2019

    Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation

    “Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease.”

    Press Release

  • Monday, January 8, 2019

    FDA Awarded Fast Track Status to CTX001 for Sickle Cell Disease

    “CTX001 uses the CRISPR gene-editing technology to increase the production of fetal hemoglobin in patients’ red blood cells.” Sickle Cell Anemia News

    Press Release

  • Monday, January 8, 2019

    GBT Plans to Submit NDA after FDA Agrees with Accelerated Approval Pathway for Voxelotor

    “Voxelotor is an oral, once-daily therapy for patients with SCD by increasing hemoglobin’s affinity for oxygen and blocks sickling of red blood cells.”

    Press Release

[/vc_column_text][/vc_column][vc_column width=”1/6″][/vc_column][/vc_row]